title: Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation.
abstract: Hyaluronic acids (HA) grafted with poly(ethylene glycol) (PEG) (PEG-g-HA) were synthesized. The materials characterization, enzymatic degradability and peptide (insulin) release from solutions of the copolymers were examined. Distribution of bioactive peptides within the polymer chain is well-known for combinations of PEG and polysaccharides as aqueous polymer two-phase systems. Insulin was preferentially partitioned into the PEG phase in a PEG/HA solution system. Enzymatic degradation of the copolymers was strongly dependent on the PEG content. Thermal analysis revealed that PEG-g-HA exhibited a variation in phase-separated structures depending on the PEG content. The solution of PEG-g-HA enabled insulin to remain in the PEG moieties dispersed in the HA matrix. Leakage of insulin from the copolymers was dependent upon the PEG content. Leakage rate of insulin from copolymer containing between 7 and 39% by weight of PEG were similar. A dramatic increase in leakage rate occurred when the PEG content was increased to greater than 39% by weight. It is considered that the loaded insulin was partitioned into the PEG moieties and became entangled with the PEG chains. The conformational change of insulin was effectively prevented in PEG-g-HA solutions, although insulin was denatured in storage of both phosphate buffered solution and HA solution. Such a heterogeneous-structured polymeric solution may be advantageous as an injectable therapeutic formulation for ophthalmic or arthritis treatment.
authors: School of Materials Science, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Tatsunokuchi, Ishikawa 923-1292, Japan.
authors: K
authors: K
authors: Moriyama
authors: T
authors: T
authors: Ooya
authors: N
authors: N
authors: Yui
mesh_terms: D001673:Biodegradation, Environmental; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004355:Drug Stability; D006820:Hyaluronic Acid / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000737:chemistry; D006821:Hyaluronoglucosaminidase / Q000378:metabolism / Q000494:pharmacology; D007267:Injections; D007328:Insulin / Q000008:administration & dosage / Q000737:chemistry*; D007700:Kinetics; D008970:Molecular Weight; D010455:Peptides / Q000008:administration & dosage / Q000737:chemistry; D011092:Polyethylene Glycols / Q000138:chemical synthesis* / Q000737:chemistry; D011487:Protein Conformation
chemical_list: D003692:Delayed-Action Preparations; D007328:Insulin; D010455:Peptides; D011092:Polyethylene Glycols; D006820:Hyaluronic Acid; D006821:Hyaluronoglucosaminidase